10,11-dihydro-5H-dibenzo(a,d)cycloheptene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 70029 |
| CHEMBL ID | 564180 |
| MeSH ID | M0040900 |
| Synonym |
|---|
| 5h-dibenzo[a,d]cycloheptene, 10,11-dihydro- |
| 10,11-dihydro-5h-dibenzo(a,d)cycloheptene |
| 6,11-dihydro-5h-dibenzo[[?],[?]][7]annulene |
| dibenzosuberane |
| 833-48-7 |
| nsc-86156 |
| nsc86156 |
| dibenzosuberane, 98% |
| inchi=1/c15h14/c1-3-7-14-11-15-8-4-2-6-13(15)10-9-12(14)5-1/h1-8h,9-11h |
| 10,11-dihydro-5h-dibenzo[a,d][7]annulene |
| CHEMBL564180 |
| FT-0666413 |
| CCG-40519 |
| dibenzocycloheptadiene |
| nsc 86156 |
| unii-gu7kln5ed5 |
| gu7kln5ed5 , |
| einecs 212-630-5 |
| 10,11-dihydro-5h-dibenzo[a,d]cycloheptene |
| dibenzo[a,d][1,4]cycloheptadiene |
| DTXSID10232254 |
| tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene |
| AKOS027320569 |
| tricyclo[9.4.0.0?,?]pentadeca-1(11),3,5,7,12,14-hexaene |
| tricyclo[9.4.0.0(3),?]pentadeca-1(11),3,5,7,12,14-hexaene |
| AS-65655 |
| 10,11-dihydro-5h-dibenzo[a,d]cycloheptene (dibenzosuberane) |
| 10,11-dihydro-5h-dibenzo[a,d]cycloheptene; dibenzosuberane |
| Q256369 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID420787 | Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM | 2009 | European journal of medicinal chemistry, Jun, Volume: 44, Issue:6 | Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||